The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia (Q28210979)

A history of antipsychotic drug development

Europe PubMed Central

title

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia (English)

0 references

0 references

L Pani

1

0 references

G L Gessa

series ordinal

2

0 references

language of work or name

English

0 references

publication date

2002

0 references

published in

Molecular Psychiatry

0 references

volume

7

0 references

page(s)

247-53

0 references

issue

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Prolactin and antipsychotic medications: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

(—)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Does olanzapine have antidepressant properties? A retrospective preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Dopamine functions in appetitive and defensive behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

The role of dopamine in the mechanism of action of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Antidepressants: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Catecholamines in the brain as mediators of amphetamine psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Presynaptic dopaminergic function in the striatum of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

The current status of the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Pharmacological actions of the atypical antipsychotic drug clozapine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Sulpiride: an antipsychotic with selective dopaminergic antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Regional effects of neuroleptics of dopamine metabolism and dopamine-sensitive adenylate cyclase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

An open study of remoxipride, a benzamide derivative, in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

An open multicentre study of the treatment of florid schizophrenia with remoxipride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Antidepressant-like activity of amisulpride in two animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Dopamine, the prefrontal cortex and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Neurobiology of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

An astroglia-linked dopamine D2-receptor action in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Structure and function of dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

The effect of aging on the D1 dopamine receptors in human frontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Working-memory mediation of adult age differences in integrative reasoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

The cerebral cortex: a case for a common site of action of antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

[Weight gain from atypical neuroleptics--an underreported adverse effect?]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Possible mechanism of antidepressant effect of L-sulpiride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Evidence for the potentiation of the antinociceptive action of morphine by bromocriptine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Dopaminergic correlates of sensory-specific satiety in the medial prefrontal cortex and nucleus accumbens of the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Amisulpride versus amineptine and placebo for the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Time Course for Effects of Sulpiride and Chlorpromazine on Monoamine Metabolite and Prolactin Levels in Cerebrospinal Fluid from Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

D1- versus D2-receptor modulation of visuospatial working memory in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

D(1) receptors in prefrontal cells and circuits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021

Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001040

7 January 2021